Posted by Michael Wonder on 21 Dec 2020
Sesen Bio submits completed biologics license application to the FDA for Vicineum and has requested priority review
21 December 2020 - BLA supported by strong Phase 3 VISTA trial data and positive analytical comparability data.
Sesen Bio today announced submission of the completed biologics license application to the FDA for Vicineum for the treatment of high risk, BCG unresponsive non-muscle invasive bladder cancer on 18 December 2020.
